<DOC>
	<DOC>NCT00783042</DOC>
	<brief_summary>The aim of this study is to investigate whether the non-invasive ultrasound method for assessment of coronary blood flow, transthoracic Doppler echocardiography-coronary flow reserve (TTDE-CFR), can be used to measure drug effects.</brief_summary>
	<brief_title>Exploratory Study of Coronary Flow Reserve Measurements, a Non-Invasive Method for Coronary Function Measurements</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Males aged 4575 years or females aged 6075 years inclusive Carotid and/or femoral atherosclerotic plaque, as assessed by carotid ultrasound examination within the last 5 years Abnormal concentrations of lipids or lipoproteins in the blood Provision of signed informed consent Treatment with statins or other lipidlowering drugs, e.g. fibrates, nicotinic acid, cholesterol absorption inhibitor, within the last 6 months before randomisation Current smoking or snuff tobacco use Major CV event (myocardial infarction (MI), stroke/ transitory ischemic attack (TIA), Acute Coronary Syndrome (ACS), revascularisation) within the last 6 months before randomisation Symptomatic carotid stenosis, atrioventricular (AV) block, QTprolongation, atrial fibrillation, sinus node disease (such as sick sinus syndrome or symptomatic bradycardia), chronic obstructive pulmonary disease (COPD) or asthma</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>TTDE-CFR</keyword>
	<keyword>coronary artery function</keyword>
	<keyword>cardiovascular biomarkers</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>Crestor</keyword>
</DOC>